Acute Effects of Rhodiola Rosea and Caffeine on Mean Propulsive Velocity Loss in Resistance Training (Rhocaf2)
The Acute Effects of 1,000 mg of Rhodiola Rosea and 3 mg/kg of Caffeine on Mean Propulsive Velocity Loss in Advanced Resistance-Trained Subjects: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
The goal of this clinical trial is to evaluate if combined acute supplementation with Rhodiola rosea and caffeine is superior to single-ingredient intake or placebo in attenuating neuromuscular fatigue in advanced resistance-trained subjects.
The main questions it aims to answer are:
Does combined supplementation attenuate mean propulsive velocity loss during heavy resistance exercise? Does combined supplementation reduce ratings of perceived exertion and increase repetitions performed to failure?
Researchers will compare four experimental conditions (placebo, caffeine alone, Rhodiola rosea alone, and combined supplementation) in a randomized crossover design to see if co-ingestion provides superior anti-fatigue benefits.
Participants will:
Complete a familiarization session to establish individual strength baselines. Attend 4 testing visits separated by a 72-hour washout period. Ingest the assigned treatment before testing. Perform a back squat fatigue protocol (3 sets at 70% 1RM) and complete perceptual evaluations.The goal of this clinical trial is to evaluate if combined acute supplementation with Rhodiola rosea and caffeine is superior to single-ingredient intake or placebo in attenuating neuromuscular fatigue in advanced resistance-trained subjects.
The main questions it aims to answer are:
Does combined supplementation attenuate mean propulsive velocity loss during heavy resistance exercise? Does combined supplementation reduce ratings of perceived exertion and increase repetitions performed to failure?
Researchers will compare four experimental conditions (placebo, caffeine alone, Rhodiola rosea alone, and combined supplementation) in a randomized crossover design to see if co-ingestion provides superior anti-fatigue benefits.
Participants will:
Complete a familiarization session to establish individual strength baselines. Attend 4 testing visits separated by a 72-hour washout period. Ingest the assigned treatment before testing. Perform a back squat fatigue protocol (3 sets at 70% 1RM) and complete perceptual evaluations.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This study is a randomized, double-blind, placebo-controlled, four-arm crossover trial designed to investigate the acute neuromuscular and ergogenic effects of single and combined supplementation with Rhodiola rosea (1,000 mg) and caffeine (3 mg/kg) in advanced resistance-trained subjects.
Neuromuscular fatigue during heavy resistance training impairs movement velocity, power output, and overall volume performance. While caffeine is a central nervous system stimulant that enhances motor unit recruitment and reduces perceived exertion, Rhodiola rosea is an adaptogen proposed to modulate central monoamines and attenuate fatigue during high-intensity effort. This protocol evaluates whether co-ingestion provides a synergistic advantage over isolated administration or placebo in maintaining movement execution quality and accelerating acute recovery.
Study Procedures:
Familiarization Session: Prior to the experimental trials, participants complete a familiarization session to establish baseline measurements and estimate 1-repetition maximum (1RM) in the barbell back squat using a two-point load-velocity method (using loads corresponding to ~1.0 m/s and ~0.5 m/s) with a linear position transducer.
Experimental Trials (4 Visits): Participants complete four experimental testing visits in a randomized, counterbalanced order, separated by a 72-hour washout period.
During each of the 4 experimental visits, participants complete the following sequence:
Supplement Ingestion: Double-blind administration of the assigned treatment:
Rhodiola placebo consists of opaque cornstarch capsules. Caffeine placebo consists of a 60 mL liquid solution containing sweetener, 3 g of sugar, and 1 g of citric acid.
Active conditions consist of 1,000 mg of Rhodiola rosea and/or 3 mg/kg of caffeine.
Pre-Exercise Evaluation: Completion of baseline perceptual questionnaires. Velocity Determination: Identification of the exact load corresponding to a Mean Propulsive Velocity (MPV) of 1.0 ± 0.03 m/s in the back squat.
Acute Fatigue Protocol: Execution of 3 sets at 70% estimated 1RM in the back squat performed to muscular failure, recording total repetitions and velocity loss across sets.
Post-Fatigue Velocity Recovery: Re-assessment of MPV using the pre-determined 1.0 m/s load at exactly 1 minute and 2 minutes post-fatigue protocol to evaluate acute neuromuscular fatigue and velocity recovery.
Perceptual Evaluation: Rating of Perceived Exertion (RPE) recorded post-exercise.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: David Gomez Castillo, PhD Candidate
- Telefonnummer: +52 2382091643
- E-Mail: david.gomezcs@uanl.edu.mx
Studieren Sie die Kontaktsicherung
- Name: Marina Medina Corrales, PhD
- Telefonnummer: +52 8115358121
- E-Mail: marina.medinacr@uanl.edu.mx
Studienorte
-
-
Nuevo León
-
San Nicolás, Nuevo León, Mexiko, 66455
- Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
-
Kontakt:
- Marina Medina Corrales, PhD
- Telefonnummer: +528115358121
- E-Mail: marina.medinacr@uanl.edu.mx
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Healthy males and females.
- Advanced resistance training experience (as defined by Santos et al., 2021): 1 to 3 years of consistent resistance training experience, demonstrating proper barbell back squat technique.
- Relative maximum strength (estimated 1RM back squat): Minimum of 150% of body mass for men, and 130% of body mass for women.
- Habitual caffeine consumers (e.g., daily intake via coffee, tea, sports gels, or energy drinks).
- Commitment to maintaining current nutritional habits and training routines throughout the study period.
- Ensured stable consumption of dietary supplements with cumulative effects (e.g., creatine, beta-alanine, nitrates, citrulline, betaine) for at least one month prior to and throughout the experimental protocol, with a commitment to not alter the dosage. Intake will be recorded and standardized.
- Availability to attend all scheduled evaluations.
- Provision of written informed consent validating full understanding of the study protocols.
Exclusion Criteria:
- Presence of cardiovascular diseases (e.g., arterial hypertension, arrhythmias) or metabolic disorders (e.g., type 1 or type 2 diabetes mellitus).
- At least one affirmative response on the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+).
- History of anabolic steroid use (less than 4 years) or use of World Anti-Doping Agency (WADA) prohibited performance-enhancing substances.
- Consumption of supplements with acute ergogenic effects (e.g., coffee, energy drinks, pre-workout supplements) within 12 hours prior to testing sessions, or failure to comply with a minimum 4-hour fasting period prior to the experimental session. (Note: Subjects violating these criteria will have their session rescheduled).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
Placebo condition consisting of opaque cornstarch capsules and a 60 mL placebo liquid solution. |
Opaque cornstarch capsules matching the active Rhodiola capsules. 60 mL liquid solution containing sweetener, 3 g of sugar, and 1 g of citric acid. |
|
Experimental: Caffeine
Single administration of caffeine alongside placebo capsules. |
Opaque cornstarch capsules matching the active Rhodiola capsules. 3 mg/kg of caffeine administered in a 60 mL liquid solution. |
|
Experimental: Rhodiola rosea
Single administration of Rhodiola rosea alongside placebo liquid solution. |
60 mL liquid solution containing sweetener, 3 g of sugar, and 1 g of citric acid. 1,000 mg of Rhodiola rosea administered in opaque capsules. |
|
Experimental: Rhodiola rosea + Caffeine
Combined administration of Rhodiola rosea and caffeine. |
3 mg/kg of caffeine administered in a 60 mL liquid solution. 1,000 mg of Rhodiola rosea administered in opaque capsules. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage Loss in Mean Propulsive Velocity (MPV)
Zeitfenster: Baseline (pre-fatigue), 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks.
|
Percentage loss in mean propulsive velocity (MPV) following the fatiguing protocol. MPV is assessed during the barbell back squat using an individualized load corresponding to an initial velocity of 1.0 ± 0.03 m/s, recorded via a linear position transducer. Percentage loss is calculated relative to pre-fatigue baseline as: [(baseline MPV - post-fatigue MPV) / baseline MPV] × 100. The fatiguing protocol consists of 3 sets to failure at 70% 1RM. |
Baseline (pre-fatigue), 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Total Number of Repetitions to Failure
Zeitfenster: Immediately upon completion of the fatiguing exercise protocol, up to 2 weeks
|
Cumulative number of successful repetitions completed across 3 sets at 70% 1RM performed to momentary muscular failure during the fatiguing protocol. Data are reported as the total number of repetitions completed per experimental condition. |
Immediately upon completion of the fatiguing exercise protocol, up to 2 weeks
|
|
Rating of Perceived Exertion (RPE)
Zeitfenster: Immediately, 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks
|
Subjective perception of effort assessed using a standardized RPE scale immediately following the fatiguing protocol to quantify internal load. |
Immediately, 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: José Raúl Hoyos Flores, PhD, Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
- Studienleiter: Marina Medina Corrales, PhD, Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
- Studienstuhl: Myriam Zaraí García Dávila, PhD, Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CEIFOD 0125028
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
IPD-Sharing-Zeitrahmen
Data will become available after publication of the main manuscript in a peer-reviewed journal and will remain accessible indefinitely.
IPD-Sharing-Zugriffskriterien
Data and supporting materials will be publicly accessible via the Open Science Framework (OSF) repository to any researcher interested in secondary or meta-analysis.
Art der unterstützenden IPD-Freigabeinformationen
- ICF
- ANALYTIC_CODE
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .